Results of a key trial of an Eisai and Biogen Alzheimer’s drug have reignited hopes that targeting amyloid beta helps arrest disease progression.
STAT+: Pharmalittle: Judge blocks required ACA coverage for preventive care; Supreme Court urged to review skinny label case
A federal judge reversed a major Obamacare provision requiring plans to cover preventive care ranging from disease screenings to pregnancy care. […]
In some of his first public remarks since getting booed on stage last month over Alzheimer’s drug remarks, Regeneron’s George Yancopoulos acknowledged in an interview he could’ve handled things differently. […]
STAT+: The U.S. Supreme Court will review a contentious Amgen patent case, but not one involving Bristol. Why?
“In taking Amgen but not Bristol, the court may have wanted to wade into this complex area one toe at a time,” one expert said. […]